Mendelian Randomization Study Linking Immune Cells, Metabolites, and Liver Cancer

A Mendelian randomization study identifies three specific immune cell traits as causal risk factors for intrahepatic cholangiocarcinoma. The analysis, published by Zhipeng Ye in 2026, suggests N-acetylleucine and fructosyllysine as potential metabolic mediators. Experimental validation in HuCC-T1 and RBE cell lines showed that disrupting the DLAT-leucine metabolic axis impaired tumor cell proliferation and migration.

Use Cases

• Validate causal links between immune phenotypes and cancer risk based on reported odds ratios and confidence intervals.
• Investigate the role of specific blood metabolites like N-acetylleucine as mediators in cancer pathways.
• Design in vitro experiments targeting metabolic axes such as DLAT-leucine based on the study's findings.
• Perform sensitivity analyses for Mendelian randomization studies, referencing the described methods for handling pleiotropy.

Strengths

• Results include specific odds ratios and p-values for three identified immune cell traits.
• Study employs a two-sample Mendelian randomization design with sensitivity analyses to address confounding.
• Findings are supported by experimental validation in two human cell lines (HuCC-T1 and RBE).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 12.8 KB, indicating limited scope, likely containing summary results rather than raw genetic data.

Provenance

Source

figshare, author Zhipeng Ye.

Collection Method

Two-sample Mendelian randomization analysis with mediation analysis and in vitro cell experiments.

Freshness

Last updated 2026-05-22 06:10:29; freshness should be verified.